CDK4/6i in HR+ SABCS 2022 Highlights with Dr. Sara Tolaney

Discussing Hormone Receptor Positive (HR+) Highlights from SABCS 2022 on usage of CDK4/6 inhibitors - Practice changing studies with Dr. Sara Tolaney, Chief - Division of Breast Oncology at Dana-Farber and Associate Professor at Harvard Medical School. CME information and credit available at: https://integrityce.com/courses/clinical-updates-from-san-antonio-hr-her2-breast-cancer-cdk-4-6-inhibitors/ Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at [email protected]